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Objectives. The propofol infusion syndrome (PRIS), a rare, often fatal, condition of unknown etiology, is defined by development
of lipemic serum, metabolic acidosis, rhabdomyolysis, hepatomegaly, cardiac arrhythmias, and acute renal failure. Methods. To
identify risk factors for and biomarkers of PRIS, a retrospective chart review of all possible PRIS cases during a 1-year period was
conducted at a level 1 trauma hospital in ICU patients over 18 years of age receiving continuous propofol infusions for ≥3d a y s .
Additional study inclusion criteria included vasopressor support and monitoring of serum triglycerides and creatinine. Results.
Seventy-two patients, 61 males (84.7%) and 11 females (15.3%), satisfied study inclusion criteria; and of these, 3 males met the study
definition for PRIS, with 1 case fatality. PRIS incidence was 4.1% with a case-fatality rate of 33%. The mean duration of propofol
infusion was 6.96 days. A positive linear correlation was observed between increasing triglyceride levels and infusion duration,
but no correlation was observed between increasing creatinine levels and infusion duration. Conclusions. Risk factors for PRIS
were confirmed as high dose infusions over prolonged periods. Increasing triglyceride levels may serve as reliable biomarkers of
impending PRIS, if confirmed in future investigations with larger sample sizes.
1. Introduction
Propofol is a popular sedative hypnotic commonly used for
induction of general anesthesia and sedation in the intensive
careunit(ICU).Propofolisastructurallydistinctalkylphenol
derivativeanestheticagent.Itispreferredoverotheravailable
agents for its rapid onset of action, rapid emergence from
sedation, and reduced likelihood of nausea and vomiting.
Propofol also provides several key physiological benefits that
make its use in the ICU favorable including reduced cerebral
metabolic demand, anticonvulsive properties, and neuropro-
tective effects [1].
Despite these advantages, propofol may rarely cause a
potentially fatal condition known as propofol infusion syn-
drome(PRIS).PRISwasfirstdescribedinchildreninthe1990s
with several adult case reports following shortly afterwards
[2–5]. The term “propofol infusion syndrome” was coined in
1998 when Bray summarized thirteen more propofol-related
deaths in children [6]. These children all exhibited a simi-
lar constellation of symptoms including metabolic acidosis,
lipemic serum, and refractory bradycardia progressing to
asystole [7, 8]. In 1996, Merinella was the first author to
suggest that a propofol reaction should be included in the
differential diagnosis of metabolic acidosis developing in
adult patients during long-term sedation with propofol [9].
Subsequently, in 1998, the first case of PRIS in an adult was
reported. In this case, nearly all of the earlier presenting
signs of PRIS in pediatric patients were described including
hypoxia, metabolic acidosis, rhabdomyolysis, renal failure,
and cardiac dysfunction [8].
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Despite over twenty years of intensive research, the com-
plete pathophysiological mechanisms responsible for PRIS
have not been identified. Potential risk factors for PRIS were
first identified in five 1992 case reports in relatively healthy
childrenwithacuteepiglottitisortracheobronchitiswhodied
after being sedated with propofol in the ICU [2, 3]. In these
cases, the pediatric patients who were treated with high dose
i n f u s i o n so fp r o p o f o lo v e rl e n g t h yp e r i o d so ft i m ed e v e l o p e d
metabolic acidosis, lipemic serum, and refractory bradycar-
dia progressing to asystole [4–6].
Theobjectivesofthisretrospectivedescriptivestudywere
to better define the incidence and demographics of PRIS in a
level 1 trauma center and to identify the most significant risk
factors for developing this condition and to further investi-
gate a correlation between increasing triglyceride levels and
duration of propofol infusion.
2. Patients and Methods
Since this investigation was an anonymous, retrospective
chart review based on pharmacy dispensing records, institu-
tional review board approval was not indicated. The present
study was a retrospective chart review investigation looking
at patients on long duration propofol infusions in the ICU
of LSU Interim Hospital in New Orleans. In order to test
the null hypothesis of no differences in the demographic
characteristics of patients receiving propofol infusions in
the ICU for three or more days and no differences in the
increases in serum triglyceride and creatinine levels over the
duration of propofol infusions, a retrospective anonymous
pharmacydatabasewasanalyzedforallICUcasesofpropofol
infusions for three or more days over the 1-year study period,
January 1–December 31, 2011. There were 72 patient cases
meeting the study inclusion criteria. Other inclusion criteria
included age of 18 years or older and nonpregnant status for
females. Of the 72 patient cases analyzed, only 3 cases met
the study case definition of PRIS, which included evidence
of rhabdomyolysis, metabolic acidosis, and cardiovascular
depression requiring vasopressor medication. All categorical
demographic variables including gender, ethnicity, comor-
bidities, medications, and vasopressor infusion were com-
pared for any statistically significant differences in their
proportionsby𝑧-testswithstatisticallysignificantdifferences
defined by 𝑃 values less than 0.05. Correlation analysis of
the increases in serum triglyceride and creatinine levels over
propofol infusion durations was conducted by comparing
the 2 linear regressions and computing their 𝑟-values, or
Pearson product-moment coefficients, with 𝑟-valuescloserto
1.0 reflecting greater correlation over time. The 𝑟-values that
were greater than 0.75 were considered clinically significant.
Lastly,anoverall𝐹-test for the coincidence of the correlation
of the increases in serum triglyceride and creatinine levels
of propofol infusion durations over time was conducted
with statistically significant differences defined by 𝑃 values
less than 0.05. All statistical calculations were conducted
using the Internet-based, public-domain, R-statistical pack-
age available at http://www.r-project.org/.
3. Results
Atotalof72patients,61males(84.7%)and11females(15.3%),
mettheinclusioncriteriaforthisstudy.Ofthese,3malesmet
the study definition for PRIS, with 1 case fatality. Although
there were no significant differences in the ethnicities
between Caucasian and African-Americans and others stud-
ied and in the comorbidities and concomitant medications in
the cases studied, there were significantly more males (𝑃<
0.0001) and more patients receiving analgesics plus sedatives
among the cases studied (Table 1). The trauma center PRIS
incidence was 4.1% with a case fatality rate of 33%. The mean
duration of propofol infusion in all cases was 6.96 days. Since
this was a retrospective review of a cohort of cases sedated
with prolonged infusions of propofol and not a prospective
observational study of similar cases, the 3 cases meeting the
study’s case definition of PRIS (rhabdomyolysis, metabolic
acidosis, and cardiovascular depression) would be defined in
a traditional manner as a period prevalence of 4.1% and only
a reflection of the true incidence of PRIS in a prospective
investigation over a one-year period of observation.
At 𝑟 = 0.807, there was a 100% greater correlational rela-
tionship between increases in serum triglycerides over time
and the duration of propofolinfusion than between increases
in serum creatinine over time and the duration of propofol
infusion (Table 2). The 𝐹-test for coincidence demonstrated
a statistically significant greater direct relationship between
increasesinserumtriglyceridesovertimeandthedurationof
propofolinfusionthanbetweenincreasesinserumcreatinine
over time and the duration of propofol infusion (Table 3,
Figure 1).Figure 1displaysthevisualcomparisonofthelinear
regression lines of increases in serum triglycerides over time
and the duration of propofol infusion and the increases in
serum creatinine over time and the duration of propofol
infusion. Of note, the creatinine levels tracked the 𝑥-axis (0-
1), remained within near-normal range (0.5–1.5mg/dL), and
were reflected in the single, combined single regression line
(Figure 1) .A l t h o u g ht h e r ew a sn od i ff e r e n c ei nt h es l o p e so r
the𝑦-interceptsof theregression lines compared,therewas a
statistically significant difference in the 𝐹-test of coincidence
between the lines indicating significantly greater correlation
of increasing triglyceride levels with duration of propofol
infusion (𝐹 = 5.773, 𝑃 = 0.04)( Figure 1).
4. Discussion
The results of the present study demonstrated a 4.1% inci-
dence of PRIS and an overall case fatality rate of 33%. The
meanpropofolinfusiondurationwas6.96days.Inthepresent
study,apositivelinearcorrelationwasnotedbetweenincreas-
ing triglyceride levels and duration of infusion, although
no significant correlation was observed between increasing
creatinine levels and duration of infusion.
In the present study, our trauma center identified a PRIS
incidence of 4.1% with a case fatality rate of 33%. However,
the true incidence of PRIS is unknown. Roberts described
1,017 critically ill patients receiving propofol infusions for
longerthan24hoursin2009andfoundtheincidenceofPRIS
to be 1.1% [9] .L a t e r ,t h eF o o da n dD r u gA d m i n i s t r a t i o n ’ sCritical Care Research and Practice 3
Table 1: Results: patient demographics (𝑁=7 2 ).
Gender (𝑛) Ethnicity (𝑛) Comorbidities (𝑛) Medications (𝑛)V a s o p r e s s o r s ( 𝑛)
Male (61)
Female (11)
Caucasian (36)
African-American (29)
Hispanic (3)
Asian (2)
Others (2)
Diabetes (9)
Hyperlipidemia (13)
Analgesics + sedatives (71)
T o t a lp a r e n t e r a ln u t r i t i o n( 1 2 )
Antipsychotics (5)
Dopamine (10)
Norepinephrine (5)
𝑧 = 4.608 𝑧 = 0.236 𝑧 = 0.240 𝑧 = 6.674 𝑧 = 1.566
𝑃 < 0.0001
∗ 𝑃 = 0.814 𝑃 = 0.818 𝑃 < 0.0001
∗ 𝑃 = 0.177
∗Statistically significant differences in demographic proportions compared, 𝑃 < 0.05.
Table 2: Results: correlation of increases in serum triglyceride and creatinine levels over propofol infusion durations.
Linear regression of serum
triglyceride levels
Linear regression of serum
creatinine levels
Combined single linear
regression line
𝑛 551 0
Slope 205 0.006 103
𝑟 (Pearson product-moment
correlation coefficient) 0.807
∗ 0.419 0.492
∗At 𝑟 = 0.807, there is a 100% greater relationship between increases in serum triglycerides over time and the duration of propofol infusion than between
increases in serum creatinine over time and the duration of propofol infusion.
Table 3: Results: overall test for the coincidence of the correlation of increases in serum triglyceride and creatinine levels over propofol
infusion durations.
Linear regression of serum
triglyceride levels
Linear regression of serum
creatinine levels
Combined single linear
regression line
𝑛 551 0
Slope 205 0.006 103
𝐹-test value 𝐹 = 5.773
𝑃 value 𝑃 = 0.04
∗
∗Statisticallysignificant,𝑃 < 0.05.A t𝑃 = 0.04,thereisasignificantlygreaterrelationshipbetweenincreasesinserumtriglycerideoverthedurationofpropofol
infusion than the relationship between increases in serum creatinine over the duration of propofol infusion, even though both measurements demonstrate
positive increases in serum levels over time.
MEDWATCH system analyzed 1,139 suspected cases of PRIS
andestimatedanincidenceofapproximately30%[10].Inad-
dition to the confusion regarding the true incidence of PRIS,
there remains no consensus on the management of PRIS
other than early recognition and discontinuation of propo-
fol.
TheclinicalmanifestationsthathavecometodefinePRIS
are wide ranging and include the development of metabol-
ic acidosis, rhabdomyolysis (skeletal > cardiac), cardiac ar-
rhythmias (including right bundle branch block, Brugada-
like syndrome, atrial fibrillation, supraventricular tachycar-
dia, ventriculartachycardia, ventricularfibrillation,andelec-
tromechanical dissociation), acute renal failure, lipemic se-
rum, hepatomegaly, and fatal cardiac arrest [6]. Electrocar-
diographic changes such as coved ST elevations in the right
precordial leads may be the first signs of impending cardio-
vascularcollapseinpatientsreceivingpropofolinfusions[11].
TheonsetofPRIS mayberelatedtoinhibitionofintracellular
energy production by mitochondria by one or both of the
following two mechanisms: (1) inhibition of transportation
of long-chain fatty acids into cells during the nutritionally
deficientstatesofcriticalillnessesand/or(2)inhibitoryeffects
on the intracellular mitochondrial respiratory chain [12].
The metabolic derangements in PRIS appear to be trig-
gered by a combination of (1) metabolic stress and high
energy demand during critical illness in susceptible patients;
(2) low carbohydrate supplies, especially in children; and (3)
a high availability of fats, as seen in propofol’s emulsion of
soybean oil and egg whites [13, 14]. However, anything that
inhibitseffectivecellularaerobicrespirationmayresultinlac-
ticacidosisthatifleftuntreatedmayresultinrhabdomyolysis,
hyperkalemia, and, ultimately, acute renal failure. Other risk
factors for PRIS include respiratory infection, severe head
injury, propofol sedation for more than 48 hours at doses
greater than 4mg/kg/hr, and increased catecholamine and
glucocorticoidserumlevels[11].Aretrospectivecohortstudy
from an adult neurosurgical ICU showed the importance of
this dose-dependent relationship [15]. Cremer et al. found4 Critical Care Research and Practice
Table 4: Differential diagnosis of PRIS.
Congenital Metabolic Medications Miscellaneous
Brugada Syndrome
MCADD
∗
Hereditary monogenic
disorders
Hypoperfusion
Hypoxia
Sepsis
Diabetic ketoacidosis
HMG-CoA reductase inhibitors
Corticosteroids
Renal toxic antibiotics
ACE inhibitors/angiotensin receptor
blockers
Renal toxic chemotherapeutic
agents
Cimetidine
Protease inhibitors
Direct muscle injury
Hypoxia from traumatic lung injury
Seizures
Immobilization
Myoclonus
Neuroleptic malignant syndrome
Contrast induced acute kidney injury
∗MCADD (medium-chain acyl-coenzyme A dehydrogenase deficiency).
1
3
5
7
9
3000
2000
1000
0
Y
X
Group 1
Group 2
Single regression
Figure1:Acomparisonofthelinearregressionlinesoftheincreases
in serum triglyceride levels over duration of propofol infusion (...)
versusincreasesinserumcreatininelevelsoverdurationofpropofol
infusion (−−−). Note: the creatinine levels (−−−)t r a c kt h e𝑥-axis
at 0-1 and are reflected in the single regression line. Although there
is no difference in the line slopes (𝑃 = 0.56)o ri nt h e𝑦-intercepts
(𝑃 = 0.515) of the regression lines, there is a statistically significant
difference in the 𝐹-test of coincidence between the lines indicating
significantlygreatercorrelationofincreasingtriglyceridelevelswith
duration of propofol infusion (𝐹 = 5.773, 𝑃 = 0.04).
that no patients showed signs of PRIS at <5mg/kg/h. How-
ever at 5-6mg/kg/h there was a 17% incidence and a 31%
incidence at >6mg/kg/h [16]. A meta-analysis by Fong et al.
found that death from PRIS was more likely if a patient was
younger than 18, received a vasopressor, or developed any
of the following symptoms: cardiac arrhythmias, rhabdomy-
olysis, impairment in renal function, metabolic acidosis, or
dyslipidemia [10].
Propofol sedation paired with catecholamine use may
havebothdirectandindirectconsequencesoncardiovascular
and skeletal muscle integrity [17]. Researchers used an ovine
m o d e lt os t u d yt h ep h y s i o l o g i ca n dp h a r m a c o l o g i cp e r t u r -
bations with concomitant propofol and catecholamine infu-
sions [18]. While catecholamines significantly increased car-
diacoutput,propofolbloodconcentrationslinearlydecreased
from baseline [17, 18]. In some instances, propofol blood
concentrations were reduced so greatly that reversal of anes-
thesia was observed. Researchers attributed the decreased
blood levels to increased first pass metabolism and clearance
secondary to increased cardiac output [17, 18]. This may
explain why patients on vasopressors require higher doses of
propofol to maintain sedation and subsequently may have a
higher correlation to PRIS development [19]. Higher doses
of propofol may be associated with both myocardial and
skeletal muscle damage subsequently resulting in eventual
cardiovascular collapse.
A differential diagnosis of PRIS is presented in Table 4.
Congenital cardiac conduction disorders, such as Brugada
Syndrome, an autosomal dominant disorder in right ventric-
ular conduction, can result in sudden death. Genetic poly-
morphisms that affect lipid metabolism, such as medium-
chain acyl-coenzyme A dehydrogenase deficiency, may also
be risk factors for PRIS and should be included in the differ-
ential diagnosis [20, 21]. Medications can also be a cause of
laboratory derangements resembling PRIS. The medications
that should be considered when ruling out PRIS either have
the capability to cause muscle injury or have been shown to
cause renal damage. Finally, miscellaneous conditions that
need to be considered in the differential diagnosis of PRIS
include the use of typical antipsychotics in bipolar patients
and the presence of ongoing seizures in an epileptic patient,
both of which can cause rhabdomyolysis [21].
There are several possible preventive measures clinicians
should consider while administering continuous propofol
infusions. These measures are based on the proposed patho-
physiologic principles of the syndrome. Critically injured
patients often have an inadequate supply of carbohydrates,
resulting in increased fat mobilization and usage [22]. This
increase in circulating fatty acid can predispose patients
to PRIS [23]. Maintaining adequate carbohydrate intake in
criticallyillpatientsmaypreventtheswitchtofatmetabolism
andthuspreventtheonsetofPRIS[24,25]. Pediatric patients
have much smaller carbohydrate stores relative to adults.
This concept may explain the lower incidence of PRIS in
adults. Researchers have proposed that a carbohydrate intakeCritical Care Research and Practice 5
of 6–8mg/kg/min can suppress fat metabolism and possibly
prevent PRIS [24]. The amount of lipid in the propofol
formulation may also contribute to PRIS onset [22]. The use
of a more concentrated propofol solution may help to reduce
this lipid burden [26].
The strengths of this retrospective study are the use of
a pharmaceutical database developed to track the use and
costs of medications and to identify any potential drug-drug
interactions. In addition, we used a preexisting clinical case
definition for PRIS and well-defined inclusion and exclusion
criteria. We also had an equally distributed Caucasian and
non-Caucasian population, being able to eliminate it as an
effect modifier. There are some limitations to the study. As
a retrospective review, we did not have a control group, such
as a cohort of dexmedetomidine-sedated patients. We have
a relatively small sample size of 72 patients, and ideally we
should have measured the creatine kinase levels over the
duration of the propofolinfusions to pick up early biomarker
e v i d e n c eo fr h a b d o m y o l y s i s .W eh a dl i m i t e dd a t ao nt h e
patient’s diagnosis and were unable to stratify our study
cohort by the two most common effect modifiers: age and
gender.
In conclusion, a presumptive diagnosis of PRIS will in-
clude clinical and laboratory confirmation of a constellation
of rhabdomyolysis, hyperkalemia, hyperlipidemia, and ARF
inadultsreceivinghighdosepropofolinfusions(>4mg/kg/h)
for prolonged (>48h) periods. Although our retrospective
chart review had a case fatality rate for PRIS of 33% consis-
tent with other investigations, the study’s incidence rate of
4.1% was four times higher than the 1.1% incidence rate in
Roberts 2009 prospective study. This considerable difference
in healthcare facility incidence may be accounted for by
several key variables including more trauma patients with
soft tissue injuries, more trauma patients with head injuries
requiringprolongedsedationformechanicalventilation,and
the greater use of propofol over other sedative hypnotics for
sedation in the ICU.
PRIS remains a complex and multifaceted clinical syn-
drome, and the overwhelming majority of patients diag-
nosed with PRIS have significant preexisting and overlap-
ping comorbidities. Patients with undiagnosed defects in
long-chain fatty acid transport and mitochondrial energy
production during critical illnesses may be at significantly
i n c r e a s e dr i s k so fP R I S .P r o p o f o ls h o u l dn o tb eu s e df o r
sedation for more than 3 days if possible. During propofol
infusions, clinicians should monitor arterial blood gases,
serum triglycerides, creatine kinase, all electrolytes (partic-
ularly potassium), serum lactate levels, liver function tests,
blood urea nitrogen, and creatinine.
Over twenty years of intensive research has failed to
demonstrate the complete pathophysiological mechanisms
responsible for propofol infusion syndrome. The diagnosis of
PRIS is usually by exclusion because patients often exhibit
other potentially fatal comorbidities including metabolic
acidosis, acute renal failure, and rhabdomyolysis. Anesthesi-
ologistandintensivistsshouldremainvigilantforthevarious
clinical manifestations of PRIS as prompt identification and
cessation of propofol use is essential to maximize patient
survival. Future large prospective, randomized controlled
trials comparing outcomes of several sedation protocols in
ICU patients will be needed to determine the true incidence
of PRIS, to identify genetically susceptible patients, and to
develop clinical guidelines for propofol sedation without
increasing risks of PRIS.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Acknowledgment
DepartmentalfundsfromLouisianaStateUniversity,Depart-
ment of Anesthesiology, were used for the preparation of this
paper.
References
[1] J. Chui, R. Mariappan, J. Mehta, P. Manninen, and L. Venka-
traghavan, “Comparison of propofol and volatile agents for
maintenance of anesthesia during elective craniotomy proce-
dures: systematic review and meta-analysis,” Canadian Journal
of Anesthesia,v o l .6 1 ,n o .4 ,p p .3 4 7 – 3 5 6 ,2 0 1 4 .
[ 2 ] T .J .P a r k e ,J .E .S t e v e n s ,A .S .C .R i c ee ta l . ,“ M e t a b o l i ca c i d o s i s
and fatal myocardial failure after propofol infusion in children:
five case reports,” British Medical Journal,v o l .30 5 ,n o .68 54 ,p p .
613–616, 1992.
[3] M. P. Okamoto, D. L. Kawaguchi, and A. N. Amin, “Evaluation
of propofol infusion syndrome in pediatric intensive care,”
American Journal of Health-System Pharmacy,v o l .6 0 ,n o .1 9 ,
pp. 2007–2014, 2003.
[ 4 ]E .B .S t e l o w ,V .P .J o h a r i ,S .A .S m i t h ,J .T .C r o s s o n ,a n dF .
S. Apple, “Propofol-associated rhabdomyolysis with cardiac
involvementinadults:chemicalandanatomicfindings,”Clinical
Chemistry,v o l .4 6 ,n o .4 ,p p .5 7 7 – 5 8 1 ,2 0 0 0 .
[5] N.D.Perrier,Y.Baerga-Varela,andM.J.Murray,“Deathrelated
to propofol use in an adult patient,” Critical Care Medicine,v o l .
2 8 ,n o .8 ,p p .3 0 7 1 – 3 0 7 4 ,2 0 0 0 .
[6] R. J. Bray, “Propofol infusion syndrome in children,” Paediatric
Anaesthesia,v o l .8 ,n o .6 ,p p .4 9 1 – 4 9 9 ,1 9 9 8 .
[7] M. A. Marinella, “Lactic acidosis associated with propofol,”
Chest,v o l .1 0 9 ,n o .1 ,a r t i c l e2 9 2 ,1 9 9 6 .
[8] J. P. Hanna and M. L. Ramundo, “Rhabdomyolysis and hypoxia
associated with prolonged propofol infusion in children,” Neu-
rology, vol. 50, no. 1, pp. 301–303, 1998.
[ 9 ]R .J .R o b e r t s ,J .F .B a r l e t t a ,J .J .F o n ge ta l . ,“ I n c i d e n c eo f
propofol-related infusion syndrome in critically ill adults: a
prospective, multicenter study,” Critical Care,v o l .1 3 ,n o .5 ,
article R169, 2009.
[10] J. J. Fong, L. Sylvia, R. Ruthazer, G. Schumaker, M. Kcomt, and
J. W. Devlin, “Predictors of mortality in patients with suspected
propofolinfusionsyndrome,”CriticalCareMedicine,vol.36,no.
8, pp. 2281–2287, 2008.
[11] K. Vernooy, T. Delhaas, O. L. Cremer et al., “Electrocardio-
graphic changes predicting sudden death in propofol-related
infusion syndrome,” Heart Rhythm,v o l .3 ,n o .2 ,p p .1 3 1 – 1 3 7 ,
2006.
[ 1 2 ]D .A .D i e d r i c ha n dD .R .B r o w n ,“ A n a l y t i cr e v i e w s :p r o p o f o l
infusion syndrome in the ICU,” Journal of Intensive Care
Medicine,v o l .2 6 ,n o .2 ,p p .5 9 – 7 2 ,2 0 1 1 .6 Critical Care Research and Practice
[13] J. Motsch and J. Roggenbach, “Propofol infusion syndrome,”
Anaesthesist, vol. 53, no. 10, pp. 1009–1024, 2004.
[ 1 4 ]L .C .O t t e r s p o o r ,C .J .K a l k m a n ,a n dO .L .C r e m e r ,“ U p d a t eo n
thepropofolinfusionsyndromeinICUmanagementofpatients
with head injury,” Current Opinion in Anaesthesiology,v o l .2 1 ,
no. 5, pp. 544–551, 2008.
[15] O .L.Cremer ,K.G.M.Moons,E.A.C.Bouman,J .E.Kruijswijk,
A. M. G. A. De Smet, and C. J. Kalkman, “Long-term propofol
infusion and cardiac failure in adult head-injured patients,” The
Lancet,v o l .3 5 7 ,n o .9 2 5 0 ,p p .1 1 7 – 1 1 8 ,2 0 0 1 .
[16] J. M. Wong, “Propofol infusion syndrome,” The American
Journal of Therapeutics,v o l .1 7 ,n o .5 ,p p .4 8 7 – 4 9 1 ,2 0 1 0 .
[17] B. Vasile, F. Rasulo, A. Candiani, and N. Latronico, “The
pathophysiologyofpropofolinfusionsyndrome:asimplename
foracomplexsyndrome,”IntensiveCareMedicine,vol.29 ,no .9 ,
p p .1 4 1 7 – 1 4 2 5 ,2 0 0 3 .
[18] J. A. Myburgh, R. N. Upton, C. Grant, and A. Mar-
tinez, “Epinephrine, norepinephrine and dopamine infusions
decrease propofol concentrations during continuous propofol
infusioninanovinemodel,”I n tensiveCar eM edicine,vol.27 ,no .
1, pp. 276–282, 2001.
[ 1 9 ]W .Z h o u ,H .J .F o n t e n o t ,S .L i u ,a n dR .H .K e n n e d y ,“ P r o p o f o l
induced alterations in myocardial beta-adrenoceptor binding
and responsiveness,” Anesthesia & Analgesia,v o l .8 9 ,n o .3 ,p p .
670–675, 1997.
[20] F. Feillet, G. Steinmann, C. Vianey-Saban et al., “Adult pre-
sentation of MCAD deficiency revealed by coma and severe
arrythmias,” I n t e n s i v eC a r eM e d i c i n e ,v o l .2 9 ,n o .9 ,p p .1 5 9 4 –
1597, 2003.
[21] A. Fudickar, B. Bein, and P. H. Tonner, “Propofol infusion
syndrome in anaesthesia and intensive care medicine,” Current
Opinion in Anaesthesiology, vol. 19, no. 4, pp. 404–410, 2006.
[22] A. R. Wolf and F. Potter, “Propofol infusion in children: when
does an anesthetic tool become an intensive care liability?”
Paediatric Anaesthesia,v o l .1 4 ,n o .6 ,p p .4 3 5 – 4 3 8 ,2 0 0 4 .
[23] P. C. A. Kam and D. Cardone, “Propofol infusion syndrome,”
Anaesthesia,v o l .6 2 ,n o .7 ,p p .6 9 0 – 7 0 1 ,2 0 0 7 .
[24] A. Wolf, P. Weir, P. Segar, J. Stone, and J. Shield, “Impaired fatty
acid oxidation in propofol infusion syndrome,” The Lancet,v o l .
357, no. 9256, pp. 606–607, 2001.
[25] T.G.ShortandY.Young,“Toxicityofintravenousanaesthetics,”
Best Practice and Research: Clinical Anaesthesiology,v o l .1 7 ,n o .
1 ,p p .7 7 – 8 9 ,2 0 0 3 .
[ 2 6 ]C .A .J .K n i b b e ,H .N a b e r ,L .P .H .J .A a r t s ,P .F .M .K u k s ,a n d
M. Danhof, “Long-term sedation with propofol 60mg ml
−1 vs.
propofol 10mg ml
−1 in critically ill, mechanically ventilated
patients,”Acta Anaesthesiologica Scandinavica,vol.48,no .3,pp .
302–307, 2004.